Scientific Advisory Board (SAB)

At Callisto BioMed, our Scientific Advisory Board is composed of world-class experts in cardiology, clinical chemistry, and diagnostics. These distinguished leaders bring decades of experience in advanced lipid testing, cardiac biomarkers, and the successful commercialization of innovative diagnostics. Their collective insights ensure that our science remains rigorous, our technologies clinically meaningful, and our path to adoption aligned with the needs of physicians and patients. By guiding our strategy and validating our approach, they play a critical role in advancing Callisto BioMed’s mission to transform cardiovascular risk assessment and improve patient outcomes.

H. Robert Superko, MD, FACC, FAHA, FASPC Preventive Cardiology KOL

  • Founder of Berkeley HeartLab; international expert in LDL/HDL subfractionation

  • Former Director, Stanford University Lipid Research Clinic and UC Berkeley Cholesterol Research Center

  • Prolific NIH-funded investigator and author in advanced lipid testing

  • Chairman/President, Cholesterol, Genetics & Heart Disease Institute; recognized with national awards in preventive cardiology

Alan H. B. Wu, PhD, DABCC, FACB
Clinical Chemistry & Cardiac Biomarkers

  • Professor of Laboratory Medicine, UCSF; Chief of Clinical Chemistry & Toxicology, Zuckerberg San Francisco General Hospital

  • Board-certified (ABCC) in Clinical and Toxicological Chemistry

  • Author of hundreds of peer-reviewed papers; global leader in cardiac biomarkers, toxicology, and pharmacogenomics

  • Co-author of international guidelines on troponin and ACS diagnostics

Business Advisory Board (BAB)

At Callisto BioMed, our Business Advisory Board is composed of seasoned leaders in diagnostics commercialization, market access, and healthcare strategy. These executives bring decades of experience scaling diagnostic businesses, navigating reimbursement and payer adoption, and building successful partnerships with health systems, reference labs, and industry stakeholders. Their collective guidance helps ensure our business model is robust, our go-to-market strategy is executable, and our commercialization roadmap aligns with real-world clinical and operational needs.

By advising on strategy, partnerships, and execution, they play a critical role in advancing Callisto BioMed’s mission to transform cardiovascular risk assessment and improve patient outcomes.

Scott Madel, MBA
Diagnostic Industry leader

  • Former President of Boston Heart Diagnostics, driving adoption of advanced cardiovascular testing

  • Expert in commercialization, market access, and partnerships with reference labs and cardiology groups

  • Advisor to diagnostics companies on growth strategy and integrating novel biomarker tests into clinical practice

  • 25+ years in life science tools across product management, marketing, and business development.

  • Former VP Marketing at HumanZyme, driving roadmap and global go-to-market programs; led major launches and partnerships at companies including Fluidigm and Agilent.

  • Full-time life science investor for the past 19 years, including angel investing and diligence leadership (Berkeley Angel Network); inventor on 4 patents and author of 5 publications (MBA, UC Berkeley Haas).

Chris Heid, MS, MBA
Investment Analyst and Investment Management